fda tirzepatide news when was approved https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) a label FDA shakes up weight loss

Renal impairment GLP-1 RAs are generally safe in patients with CKD and have demonstrated nephroprotective effects in the FLOW trial, where semaglutide significantly reduced the composite renal endpoint (hospitalization for acute kidney injury, sustained 50% decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or renal death) in patients with type 2 diabetes and CKD [15]

J Hematol Oncol 13 , 64 (2020)

Additionally, tirzepatide suppresses glucagon secretion, slows gastric emptying, and promotes satiety through central nervous system pathways, leading to reduced caloric intake and weight loss

In addition to avoiding potential issues like constipation, dry skin, or lightheadedness, adequate water intake is important because its associated with satiety and fullness as well